Author of

• 17629

  +

  P2.03b - Poster Session with Presenters Present (ID 465)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17719

    +

    P2.03b-090 - A CTLA-4 Antagonizing DNA Aptamer with Anti-Tumor Effect (ID 6008)

    14:30 - 14:30  |  Author(s): B. Huang
    • Abstract
    • Slides

    Background:
    The discovery of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade and its successful clinical translation has revolutionized the concept of cancer immunotherapy. Although immunecheckpoint-targeting antibody has shown impressive results in a diverse array of cancers, their cell-based manufacturing process influences production capacity and cause variation between batches. Aptamers are synthetic DNA or RNA oligonucleotides that encompass antibody-mimicking functions. With its chemically synthetic nature, aptamer can be produced in large scale with controllable batch variations and lower manufacturing cost.
    
    Methods:
    Here, we report the development of a CTLA-4 antagonizing DNA aptamer, termed aptCTLA-4, using the cell-based SELEX and next-generation sequencing.
    
    Results:
    The aptCTLA-4 exhibits good binding affinity (dissociation constant, 11.8 nM). In vitro lymphocyte proliferation assays demonstrated that the aptCTLA-4 promotes T cell proliferation, and in vivo murine syngeneic tumor models further revealed its tumor-inhibitory effects.
    
    Conclusion:
    Our data suggest the translational potential of the aptCTLA-4 to be developed into a therapeutic aptamer.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.